Trisalus life sciences director Wahlstrom Mats buys 22,750 in stock - Investing.com
| TLSIW Stock | 1.00 0.07 7.53% |
Slightly above 55% of TriSalus Life's sophisticated investors are presently thinking to get in. The analysis of overall sentiment of trading TriSalus Life Sciences stock suggests that some investors are interested at this time. TriSalus Life's investing sentiment can be driven by a variety of factors including economic data, TriSalus Life's earnings reports, geopolitical events, and overall market trends.
TriSalus |
Trisalus life sciences director Wahlstrom Mats buys 22,750 in stock Investing.com
Read at news.google.com
 |
TriSalus Life Fundamental Analysis
We analyze TriSalus Life's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TriSalus Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TriSalus Life based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
TriSalus Life is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
TriSalus Life Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TriSalus Life stock to make a market-neutral strategy. Peer analysis of TriSalus Life could also be used in its relative valuation, which is a method of valuing TriSalus Life by comparing valuation metrics with similar companies.
Peers
TriSalus Life Related Equities
| LIVN | LivaNova PLC | 4.20 | ||||
| TMCI | Treace Medical | 0.00 | ||||
| SRDX | SurModics | 0.45 | ||||
| ELMD | Electromed | 0.69 | ||||
| INGN | Inogen | 0.73 | ||||
| LUNG | Pulmonx Corp | 1.25 | ||||
| SGHT | Sight Sciences | 1.28 | ||||
| APYX | Apyx Medical | 1.63 | ||||
| NPCE | Neuropace | 2.80 | ||||
| RCEL | Avita Medical | 3.25 |
Additional Tools for TriSalus Stock Analysis
When running TriSalus Life's price analysis, check to measure TriSalus Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TriSalus Life is operating at the current time. Most of TriSalus Life's value examination focuses on studying past and present price action to predict the probability of TriSalus Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TriSalus Life's price. Additionally, you may evaluate how the addition of TriSalus Life to your portfolios can decrease your overall portfolio volatility.